Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Isn't Punit's uncle the common denominator between INO and ONCS?
He's on the board of both companies?
I have to agree that we have now passed the "7th inning stretch."
It's the bottom of the 7th inning and we're going through the bottom of our batting order. Luckily, we have our heavy hitters coming up in the 8th and 9th innings, as we're currently down 5 milestones.
Here's to hoping that we hit a couple of them out of the park, and rally big to win in 2014!
I'm all for the surprises!
As long as they're positive ones. :)
I believe one has to look at any dependencies which may exist among the milestones.
In other words, which milestones do we believe will happen first, and which are dependent on others. And why.
Can anyone list the "order" the success of the milestones will likely be made public?
That would be ideal.
(I'm a man of few words today.)
+1000
I was about to say the same thing. :)
We need more volume to confirm some of these moves.
This is just the beginning...
Just as in the natural world...
Interesting and exciting events can be so fleeting. :)
Still, good things lie ahead!
Nice article out by Zacks this morning on ONCS:
http://finance.yahoo.com/news/oncosec-oncs-unique-drug-delivery-131500092.html
I could possibly see some additional pressure on the PPS in the absence of PR and with the rout in financial markets still in play.
But we've seem to have found a base near 0.40 and the worst I could see this going from here is the upper 0.30s. That's not much profit considering the unlimited losses a short seller would incur if the stock pops on ANY of the milestones?
The risk/reward simply "should not" be there for short-sellers. But, as you say, maybe they know something we do not. But I find that difficult.
In fact, all of this week?
Who in their right mind would short ONCS at these levels? Especially with milestones (and subsequent PR) likely to start happening at any point now?
I understand your sentiment at a personal level.
Part of the reason I'm in ONCS is because I lost my father to Melanoma.
You should be out riding your bike in the TN weather.
Or has it turned too cold there?
I agree, Fur, and have actually been accumulating at these levels in anticipation of a significant run-up before EOY and into next year. I truly believe that it will happen.
Knowing that nothing is guaranteed in biotech, however, gives me cause for an occasional pause. That's all.
Onward and upward we go!
Sal--I agree with you completely. This thing is likely to skyrocket, and soon. I'm personally betting on it.
However, most of us with large investments here tirelessly attempt to uncover all unturned stones, almost to the point of paranoia. As good as everything appears, there is almost NEVER a "slam dunk" in biotech.
I've learned the hard way before. :)
Extremely well stated. We will all learn soon enough which of the three scenarios you outlined will come to fruition.
The only "red flag" that I see is one of Punit's obtuse comments: "We are on track to hit all milestones by the end of 2014. The only thing which could stop us is bad data."
What could be meant by "bad data?" Is it a mysterious 30th patient? (Or has that already been debunked?) Is it bad MCC data? What could it possibly be?
Here's to hoping that it's nothing!
How does one become a market maker in general?
A market maker for ONCS?
Just curious.
I don't know anything...
But I bought another 20K block at 2:23 this afternoon at 0.405.
Patience is only needed for a few more months and we'll see triple digits (in pennies). Looking forward to it.
Sorry, phone screwed up.
Make that 25K shares and 350K shares long and strong!
Buying at these low levels could be addicting.
Added 250 more shares @ 0.415 during lunch in Bar Harbor. Can't resist these prices with all that we have coming up.
30 shares, long and strong.
Punitive better deliver the goods! :)
I've grown weary of all the predictions which seem to never pan out. :(
When it comes it comes.
I'm just being patient with the belief that we'll be rewarded "sometime" during the next 3 months. :)
Where has it been posted?
Inquiring minds want to know. :)
Bump.
Can you read Punit's mind? Only he knows what he meant.
Most everything else, is pure conjecture.
More data and P2B trial is due out before EOY. A partnership would be gravy.
Shaking the tree big time today.
I suppose it's apropos being September and the leaves falling.
Agreed.
Phase 2b and a Partnership.
Let's get it on ONCS!
Thanks Fur.
How many MMs do we have for ONCS?
I've got Level II quotes at Scottrade, but none show up for ONCS.
It looks like they changed their mind. :(
I wonder how long we will be in the 0.40s.
Only the Shadow (er, Mensa) knows...
When this thing will surge higher.
Why don't we all admit that the expected "pop" will happen when we all least expect it.
Patience, grasshoppers. :)
Agreed. Big question. How does B16 correlate to human studies?
Any help, dear Mensa?
I just think we need to be careful and fully understand what is pure speculation (from US) and what is stated fact (from ONCS).
There should be no expectations other than good news is on the way before the end of the year. Nothing more than that.
OK, we've got three months to wait, and the company has never been this well positioned. Just understand that. Nothing more. Anything else is pure conjecture.
It will be interesting to see if we can hold support at 0.50.
Or if we break lower in the absence of the expected PR.
Wasn't someone going to call Acorn?
If I recall, someone posted that they would be calling Acorn last week.
I hope they did so and can report back to us...
9:00 a.m. EST is usually the latest you'll see news released before the market opens.
Most often, companies release at 8:00 a.m. but of course there are variances to this. INO tends to release at 4:00 a.m. for example.
That's the idea.
Let the bidding wars begin!
Mensa--isn't Merck the company to watch?
Based on the previous work that Pierce did with MK-3475?
Thanks Fur and Laser!
That was my understanding, too.
I thought about responding to the YMB post, but I just wanted someone to respond who has done more DD than me and can speak to it better.
BMY beat ONCS to the punch?
This may be old news, but it was recently posted at the YMB. Thoughts?
(Reuters) - The U.S. Food and Drug Administration has granted a six-month, priority review to Bristol-Myers Squibb Co's application for immuno-oncology drug Opdivo as a treatment for previously treated melanoma, the company said on Friday.
The FDA decision is due by March 30, 2015.
Bristol said European regulators have also agreed to an accelerated review of the drug as a treatment for advanced melanoma.
Opdivo, or nivolumab, is part of a promising new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fighting cells.
Merck & Co Inc's Keytruda, or pembrolizumab, became the first PD-1 drug available in the United States, when the FDA earlier this month approved its use for patients with advanced melanoma who are no longer responding to other therapies.
Companies including Roche Holding AG and AstraZeneca Plc are also developing PD-1 pathway drugs for a variety of cancers, including lung cancer. Some analysts expect the new class could generate more than $30 billion in annual sales worldwide by 2025.
Bristol said Opdivo was also designated by the FDA as a "breakthrough" melanoma therapy. The agency earlier this year designated the drug as a breakthrough therapy for patients with Hodgkin lymphoma who had failed other treatments.
In April, Bristol initiated a "rolling" submission with the FDA for Opdivo use in certain patients with a type of non-small cell lung cancer. The company said it expects to complete that application by the end of the year.
I agree Sal... tempering expectations is important.
But there are about 5 catalysts which are supposed to hit this year, and we're at the very beginning stages of the "running out of time" rule to get them all done in the next 8-10 weeks.
As such, we may see the low-to-mid .40s again before we see the 0.60s and that will ultimately "mute" any significant stock appreciation for many of us.
Again, nothing short of a partnership will drive this thing much higher and be able to sustain it before PPS decay starts again.
I suppose that I'm speaking for many that we're starting to get impatient. What happened to the "run-ups" which everyone was projecting? I believe that most of the current PPS is based on a rebound from a technically oversold stock, and not based on any fundamentals...
We need more fundamentals and we need more news.
Monday better bring some VERY good news.
Or there will be VERY many disappointed people here. :)
In the meantime, enjoy college football, and all that the weekend has to offer! GLTA!